139 related articles for article (PubMed ID: 35158021)
1. SIRT1 attenuates neuroinflammation by deacetylating HSPA4 in a mouse model of Parkinson's disease.
Yang Y; Zhang S; Guan J; Jiang Y; Zhang J; Luo L; Sun C
Biochim Biophys Acta Mol Basis Dis; 2022 May; 1868(5):166365. PubMed ID: 35158021
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of IRF8 alleviates neuroinflammation through regulating microglial activation in Parkinson's disease.
Ma L; Mi N; Wang Z; Bao R; Fang J; Ren Y; Xu X; Zhang H; Tang Y
J Chem Neuroanat; 2024 Jul; 138():102424. PubMed ID: 38670441
[TBL] [Abstract][Full Text] [Related]
3. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
[TBL] [Abstract][Full Text] [Related]
4. Programmed Death-1 Deficiency Aggravates Motor Dysfunction in MPTP Model of Parkinson's Disease by Inducing Microglial Activation and Neuroinflammation in Mice.
Cheng YY; Chen BY; Bian GL; Ding YX; Chen LW
Mol Neurobiol; 2022 Apr; 59(4):2642-2655. PubMed ID: 35142987
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson's Disease.
Pariyar R; Bastola T; Lee DH; Seo J
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216503
[TBL] [Abstract][Full Text] [Related]
6. Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra.
Heng Y; Zhang QS; Mu Z; Hu JF; Yuan YH; Chen NH
Toxicol Lett; 2016 Jan; 243():7-21. PubMed ID: 26723869
[TBL] [Abstract][Full Text] [Related]
7. The Neuroprotective Effects of GPR4 Inhibition through the Attenuation of Caspase Mediated Apoptotic Cell Death in an MPTP Induced Mouse Model of Parkinson's Disease.
Haque ME; Azam S; Akther M; Cho DY; Kim IS; Choi DK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925146
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-124 regulates the expression of p62/p38 and promotes autophagy in the inflammatory pathogenesis of Parkinson's disease.
Yao L; Zhu Z; Wu J; Zhang Y; Zhang H; Sun X; Qian C; Wang B; Xie L; Zhang S; Lu G
FASEB J; 2019 Jul; 33(7):8648-8665. PubMed ID: 30995872
[TBL] [Abstract][Full Text] [Related]
9. Treadmill exercise produces neuroprotective effects in a murine model of Parkinson's disease by regulating the TLR2/MyD88/NF-κB signaling pathway.
Koo JH; Jang YC; Hwang DJ; Um HS; Lee NH; Jung JH; Cho JY
Neuroscience; 2017 Jul; 356():102-113. PubMed ID: 28527958
[TBL] [Abstract][Full Text] [Related]
10. TLR4 deficiency has a protective effect in the MPTP/probenecid mouse model of Parkinson's disease.
Shao QH; Chen Y; Li FF; Wang S; Zhang XL; Yuan YH; Chen NH
Acta Pharmacol Sin; 2019 Dec; 40(12):1503-1512. PubMed ID: 31388087
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-30e regulates neuroinflammation in MPTP model of Parkinson's disease by targeting Nlrp3.
Li D; Yang H; Ma J; Luo S; Chen S; Gu Q
Hum Cell; 2018 Apr; 31(2):106-115. PubMed ID: 29274035
[TBL] [Abstract][Full Text] [Related]
12. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
13. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
14. MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration.
Lee E; Hwang I; Park S; Hong S; Hwang B; Cho Y; Son J; Yu JW
Cell Death Differ; 2019 Jan; 26(2):213-228. PubMed ID: 29786072
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
Harrison IF; Dexter DT
Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective Effect of Ceftriaxone on MPTP-Induced Parkinson's Disease Mouse Model by Regulating Inflammation and Intestinal Microbiota.
Zhou X; Lu J; Wei K; Wei J; Tian P; Yue M; Wang Y; Hong D; Li F; Wang B; Chen T; Fang X
Oxid Med Cell Longev; 2021; 2021():9424582. PubMed ID: 34938384
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol alleviates MPTP-induced motor impairments and pathological changes by autophagic degradation of α-synuclein via SIRT1-deacetylated LC3.
Guo YJ; Dong SY; Cui XX; Feng Y; Liu T; Yin M; Kuo SH; Tan EK; Zhao WJ; Wu YC
Mol Nutr Food Res; 2016 Oct; 60(10):2161-2175. PubMed ID: 27296520
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of paeonol on methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid-induced Parkinson's disease in mice.
Shi X; Chen YH; Liu H; Qu HD
Mol Med Rep; 2016 Sep; 14(3):2397-404. PubMed ID: 27484986
[TBL] [Abstract][Full Text] [Related]
19. CD44 deficiency represses neuroinflammation and rescues dopaminergic neurons in a mouse model of Parkinson's disease.
Wang Y; Li L; Wu Y; Zhang S; Ju Q; Yang Y; Jin Y; Shi H; Sun C
Pharmacol Res; 2022 Mar; 177():106133. PubMed ID: 35182746
[TBL] [Abstract][Full Text] [Related]
20. BMAL1 regulation of microglia-mediated neuroinflammation in MPTP-induced Parkinson's disease mouse model.
Liu WW; Wei SZ; Huang GD; Liu LB; Gu C; Shen Y; Wang XH; Xia ST; Xie AM; Hu LF; Wang F; Liu CF
FASEB J; 2020 May; 34(5):6570-6581. PubMed ID: 32246801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
